Intra-Cellular Therapies
ITCI
£102.03
Share price
-0.04%
Change (1 day)
87.49%
Change (1 year)
Categories
P/S ratio for Intra-Cellular Therapies (ITCI)
P/S ratio as of April 2025 (TTM): 20.6
According to Intra-Cellular Therapies's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 12.2. At the end of 2024 the company had a P/S ratio of 13.2.
P/S ratio history for Intra-Cellular Therapies from 2014 to 2024
PS ratio at the end of each year
| Year | P/S ratio | Change |
|---|---|---|
| 2024 | 13.2 | -11.36% |
| 2023 | 14.9 | -25.87% |
| 2022 | 20.1 | -61.45% |
| 2021 | 52.2 | -54.05% |
| 2020 | 114 | -99.64% |
| 2019 | > 1000 | |
| 2018 | N/A | |
| 2017 | N/A | |
| 2016 | N/A | -100% |
| 2015 | > 1000 | 7862.53% |
| 2014 | 951 |
P/S ratio for similar companies or competitors
| Company | P/S ratio | P/S ratio differencediff. | Country |
|---|---|---|---|
 | N/A | N/A | 🇺🇸 USA |
 | 1.20 | -94.16% | 🇺🇸 USA |
 | 5.35 | -74.10% | 🇺🇸 USA |